Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells
Open accessAbstract
A structurally diverse set of 147 per- and polyfluoroalkyl substances (PFAS) was screened in a panel of 12 human primary cell systems by measuring 148 biomarkers relevant to (patho)physiological pathways to inform hypotheses about potential mechanistic effects of data-poor PFAS in human model systems. This analysis focused on immunosuppressive activity, which was previously reported as an in vivo effect of perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), by comparing PFAS responses to four pharmacological immunosuppressants. The PFOS response profile had little correlation with reference immunosuppressants, suggesting in vivo activity does not occur by similar mechanisms. The PFOA response profile did share features with the profile of dexamethasone, although some distinct features were lacking. Other PFAS, including 2,2,3,3-tetrafluoropropyl acrylate, demonstrated more similarity to the reference immunosuppressants but with additional activities not found in the reference immunosuppressive drugs. Correlation of PFAS profiles with a database of environmental chemical responses and pharmacological probes identified potential mechanisms of bioactivity for some PFAS, including responses similar to ubiquitin ligase inhibitors, deubiquitylating enzyme (DUB) inhibitors, and thioredoxin reductase inhibitors. Approximately 21% of the 147 PFAS with confirmed sample quality were bioactive at nominal testing concentrations in the 1-60 micromolar range in these human primary cell systems. These data provide new hypotheses for mechanisms of action for a subset of PFAS and may further aid in development of a PFAS categorization strategy useful in safety assessment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a study of potential immunosuppressive activity in a panel of 12 primary human cell systems and 148 relevant biomarkers, only 21% of the 147 PFAS analyzed showed bioactivity; PFOS activity profile showed little correlation with reference immunosuppressants; PFOA profile shares some features with dexamethasone but also unique characteristics.
“In a study of potential immunosuppressive activity in a panel of 12 primary human cell systems and 148 relevant biomarkers, only 21% of the 147 PFAS analyzed showed bioactivity. The activity profile of PFOS showed little correlation with the reference immunosuppressants, suggesting that in vivo activity may occur via different mechanisms. The activity profile of PFOA shares some common features”
From The EU’s Per- and Polyfluoroalkyl Substances (PFAS) Ban: A Case of Policy over Science (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings
Lau, C., Anitole, K., Hodes, C., Lai, D., Pfahles-Hutchens, A., & Seed, J. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm128 · Cited by 2,620 · cited 1× · see citing works
“Also of note was the lack of any PFAS with a liver toxicity signature assigned for both sample replicates at any concentration although liver toxicity in animals has been associated with a number of PFAS including PFOA and PFOS (Lau et al., 2007).”
A Never-Ending Story of Per- and Polyfluoroalkyl Substances (PFASs)?
Wang, Z., DeWitt, J. C., Higgins, C. P., & Cousins, I. T. (2017) · Environmental Science & Technology · doi:10.1021/acs.est.6b04806 · Cited by 1,921 · cited 1× · see citing works
“Extensive studies of several of the highly produced members of the class have demonstrated potential for adverse health consequences to humans as well as highly pervasive and persistent exposures (Wang et al., 2017; Cousins et al., 2019).”
Ahmed, S., Gogal, R., & Walsh, J. (1994) · JIM - Journal of Immunological Methods · doi:10.1016/0022-1759(94)90396-4 · Cited by 1,450 · cited 2× · see citing works
“SRB was performed by staining cells with 0.1% SRB after fixation with 10% TCA and reading wells at 560 nm. Viability and proliferation of PBMC (T cells) was quantified by Alamar Blue reduction (Ahmed et al., 1994) for the SAg and BT systems.”
InfluentialProteasome inhibitors: from research tools to drug candidates.
Kisselev, A., & Goldberg, A. (2001) · Chemistry and Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,176 · cited 2× · see citing works
“Proteasome inhibitors are used therapeutically as anticancer agents and drive cancer cells into apoptosis at appropriate concentrations (Kisselev and Goldberg, 2001).”
Fu, J., Gaetani, S., Oveisi, F., Verme, J., Serrano, A., de Fonseca, F. D., Rosengarth, A., Luecke, H., Giacomo, B. D., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,113 · cited 2× · see citing works
“Profiles for PPARa agonists oleylethanolamide and gemfibrozil and PPARg agonists rosiglitazone and pioglitazone at concentrations exceeding their effective in vitro reported ones are shown in Figure 8 (Fu et al., 2003; De Filippis et al., 2015; Young et al., 1998; Sakamoto et al., 2000).”
Risk to human health related to the presence of perfluoroalkyl substances in food
Panel), E. P. O. C. I. T. F. C. (. C., Schrenk, D., Bignami, M., Bodin, L., Chipman, J. K., del Mazo, J., Grasl‐Kraupp, B., Hogstrand, C., Hoogenboom, L. (., Leblanc, J., et al. (2020) · EFSA Journal · doi:10.2903/j.efsa.2020.6223 · Cited by 989 · cited 3× · see citing works
“…Food Safety Authority extensively reviewed both animal studies and human epidemiological associations of PFAS (primarily PFOA and PFOS) and reported decreased T cell-dependent antibody responses and reduced antibody response to vaccinations as critical indicators of PFAS effects (EFSA, 2020).”
Mechanisms of action of cyclosporine.
Matsuda, S., & Koyasu, S. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00192-2 · Cited by 813 · cited 1× · see citing works
“Presumably, this activity results from the known mechanism of action for cyclosporin A: complexing with cyclophilin and subsequent inhibition of the phosphatase activity of calcineurin preventing nuclear translocation and activation of NFAT transcription factors (Matsuda and Koyasu, 2000).”
The role of Peroxisome Proliferator-Activated Receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. (2020) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2020.154338 · Cited by 654 · cited 2× · see citing works
“The PPARs primarily regulate metabolism in many cell types, which impacts the differentiation, expansion, and fate commitment of immune cells (Christofides et al., 2021).”
(2013) · doi:10.15620/cdc:105345 · Cited by 634 · cited 1× · see citing works
“These concentrations exceed by two orders of magnitude the serum levels measured in the 2015–16 NHANES study, which reported geometric means of 3.8 nM PFOA and 9.4 nM PFOS for the general US population (CDC, 2019).”
InfluentialStockholm Convention on Persistent Organic Pollutants
Templeton, J. (2020) · Essential Concepts of Global Environmental Governance · doi:10.4324/9780367816681-99 · Cited by 558 · see citing works
Gaballah, S., Swank, A., Sobus, J. R., Howey, X. M., Schmid, J., Catron, T., McCord, J., Hines, E., Strynar, M., & Tal, T. (2020) · Environmental Health Perspectives · doi:10.1289/ehp5843 · Cited by 437 · cited 2× · see citing works
“One chemical, ammonium perfluoro-2-methyl-3-oxahexanoate (GenX), was solubilized in H 2 O as it was known to be unstable in DMSO (Gaballah et al., 2020; Liberatore et al., 2020).”
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419 · cited 1× · see citing works
“…contained all tested concentrations of dexamethasone, a glucocorticoid causing immunosuppression through activation of the glucocorticoid receptor resulting in transrepression (repression of gene activation by other transcription factors) of many inflammatory cytokine genes (Stahn et al., 2007).”
Steenland, K., Tinker, S., Frisbee, S. J., DUCATMAN, A. M., & Vaccarino, V. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp279 · Cited by 374 · cited 1× · see citing works
“…higher as, for example, those seen in the population exposed to heavily contaminated drinking water from industrial processes in West Virginia where geometric mean PFOA concentration was 193 nM with extremes up to 42 mM and mean PFOS of 44 nM ranging up to 1.5 mM (Steenland et al., 2009).”
InfluentialDiscovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.
Knight, S., Adams, N. D., Burgess, J. L., Chaudhari, A., Darcy, M., Donatelli, C. A., Luengo, J., Newlander, K., Parrish, C., Ridgers, L., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 365 · cited 2× · see citing works
“Similarity analysis at this concentration indicated a high correlation of the profile with that of omipalisib, a phosphoinositide 3-kinase inhibitor that blocks activity of the mammalian target of rapamycin complex 1 (mTORC1) (Knight et al., 2010).”
The temporal profile of calcineurin inhibition by cyclosporine in vivo.
Halloran, P., Helms, L., Kung, L., & Noujaim, J. (1999) · Transplantation · doi:10.1097/00007890-199911150-00023 · Cited by 326 · cited 2× · see citing works
“Note that this concentration is greater than typical pharmacological exposures in patients treated with cyclosporin A as immunosuppressant therapy (with a maximum plasma concentration, Cmax, of < 1-2 mM) (Halloran et al., 1999).”
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1006/bbrc.2000.3868 · Cited by 313 · cited 2× · see citing works
“Profiles for PPARa agonists oleylethanolamide and gemfibrozil and PPARg agonists rosiglitazone and pioglitazone at concentrations exceeding their effective in vitro reported ones are shown in Figure 8 (Fu et al., 2003; De Filippis et al., 2015; Young et al., 1998; Sakamoto et al., 2000).”
Crosstalk and Interplay between the Ubiquitin-Proteasome System and Autophagy
Ji, C. H., & Kwon, Y. T. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0115 · Cited by 313 · cited 2× · see citing works
“The testing concentrations selected for this study were determined based on the ability to generate a universal solubilithe latter process known to be stimulated by inhibition of proteasome activity (Ji and Kwon, 2017).”
InfluentialZhang, W., Pang, S., Lin, Z., Mishra, S., Bhatt, P., & Chen, S. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2020.115908 · Cited by 280 · cited 1× · see citing works
“Indeed, PFAS have been shown to have significant effects on several properties including serum protein binding and bioaccumulation that may impact actual cellular exposure levels (Yang, D. et al., 2020; Zhang, W. et al., 2020).”
Suppression of Humoral Immunity in Mice following Exposure to Perfluorooctane Sulfonate
Peden‐Adams, M. M., Keller, J. M., EUDALY, J. G., Berger, J., Gilkeson, G. S., & Keil, D. E. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn059 · Cited by 278 · cited 2× · see citing works
“For instance, PPARa and PPARg are known molecular targets for PFAS, and among numerous bioactivities associated with these receptors in the literature are effects on the immune system, primarily categorized as anti-inflammatory and suggested as a mechanism for PFAS immunosuppression (Christofides et al., 2021; Peden-A…”
DeWitt, J., Shnyra, A., Badr, M., Loveless, S., Hoban, D., Frame, S., Cunard, R., Anderson, S., Meade, B., Peden-Adams, M., et al. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440802209804 · Cited by 272 · cited 9× · see citing works
“Other studies have suggested that alterations in IgG secretion in mice exposed to PFOA may occur independently of systemic toxicity and stress-related corticosterone increases (DeWitt et al., 2009a), noting that IgG secretion in the BT system in BioMAP was unaffected by PFOA.”
InfluentialTranscription coactivators for peroxisome proliferator-activated receptors.
Yu, S.-T., & Reddy, J. (2007) · Biochimica et Biophysica Acta · doi:10.1016/j.bbalip.2007.01.008 · Cited by 252 · cited 1× · see citing works
“PPARs are also known to function in large complexes that include various co-activators and co-repressors that impart cell-type and tissue-specific effects, with considerable species differences including in immune responses (Yu and Reddy, 2007; Corsini et al., 2014).”
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Hammitzsch, A., Tallant, C., Fedorov, O., O'Mahony, A., Brennan, P., Hay, D., Martínez, F., Al-Mossawi, M. H., Dewit, J., Vecellio, M., et al. (2015) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1501956112 · Cited by 239 · cited 1× · see citing works
“This panel has been extensively used in pharmaceutical and consumer products research for characterization of product candidates (O’Mahony et al., 2018; Betts et al., 2018; Hammitzsch et al., 2015; Shah et al., 2017; Simms et al., 2021; Singer et al., 2019).”
Griffith, E. C., Su, Z., Niwayama, S., Ramsay, C. A., Chang, Y.-H., & Liu, J. O. (1998) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.95.26.15183 · Cited by 238 · cited 1× · see citing works
“The other major correlated profile was that of the fumagillin analog TNP-40, which inhibits angiogenesis through irreversible inactivation of methionine aminopeptidase-2 (MetAP2), blocking endothelial cell proliferation in vitro and angiogenesis in vivo (Griffith et al., 1998).”
tcpl: the ToxCast pipeline for high‐throughput screening data
Filer, D., Kothiya, P., Setzer, W. R., Judson, R., & Martin, M. T. (2016) · Bioinform. · doi:10.1093/bioinformatics/btw680 · Cited by 221 · cited 2× · see citing works
“0) (Filer et al., 2017) using methods to identify lowest observable effect concentration for BSK data rather than curve-fitting these data as is done for most other ToxCast data.”
InfluentialOjo, A. F., Peng, C., & Ng, J. C. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.124863 · Cited by 221 · cited 2× · see citing works
“ALTEX 40(2), 2023 267 as well as contribute to risk analysis in facilitating grouping of PFAS from complex mixtures that may have additive or other interactive activities (Ojo et al., 2020).”
Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances
OECD (2021) · OECD Series on Risk Management of Chemicals · doi:10.1787/e458e796-en · Cited by 220 · cited 1× · see citing works
“…of PFAS, the OECD now defines PFAS as substances with a minimum of one perfluorinated carbon, which results in a list of PFAS that may approach 40,000 substances, with more stringent definitions of PFAS structures resulting in shorter lists in the thousands (Williams et al., 2022; OECD, 2021).”
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms
Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., Dix, D. J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2914 · Cited by 211 · cited 3× · see citing works
“…as (patho)physiologically relevant screening assays for evaluating adverse effects was previously demonstrated through testing pharmaceuticals and clinical candidates as well as environmental chemicals in the EPA’s ToxCast program (Kleinstreuer et al., 2014; Berg et al., 2006; Singer et al., 2019).”
Self-citationPerfluorinated compounds: Emerging POPs with potential immunotoxicity
Corsini, E., Luebke, R. W., Germolec, D. R., & DeWitt, J. C. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.01.038 · Cited by 207 · cited 1× · see citing works
“PPARs are also known to function in large complexes that include various co-activators and co-repressors that impart cell-type and tissue-specific effects, with considerable species differences including in immune responses (Yu and Reddy, 2007; Corsini et al., 2014).”
Yang, C., Tarkhov, A., Marusczyk, J., Bienfait, B., Gasteiger, J., Kleinoeder, T., Magdziarz, T., Sacher, O., Schwab, C., Schwoebel, J., et al. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500667v · Cited by 193 · cited 2× · see citing works
“…in Table S1 1 , along with their average mass (g/mol), the analytical quality control grades on the solubilized chemical samples (stock samples), the final concentrations used in screening in the BioMAP assays, and the structural categories based on ChemoType ToxPrints (Yang, C. et al., 2015)”
Why is high persistence alone a major cause of concern?
Cousins, I., Ng, C. A., Wang, Z.-Y., & Scheringer, M. (2018) · Environmental Science: Processes & Impacts · doi:10.1039/c8em00515j · Cited by 191 · cited 1× · see citing works
“Extensive studies of several of the highly produced members of the class have demonstrated potential for adverse health consequences to humans as well as highly pervasive and persistent exposures (Wang et al., 2017; Cousins et al., 2019).”
Bonvini, P., Zorzi, E., Basso, G., & Rosolen, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404528 · Cited by 177 · cited 1×
“Two PFAS, 3-(perfluorooctyl)propanol and 3,3-bis(trifluoromethyl)-2-propenoic acid, matched the profile of bortezomib, a proteasome inhibitor that binds to the catalytic site of the 26S proteasome (Bonvini et al., 2007).”
Armitage, J., Wania, F., & Arnot, J. (2014) · Environmental Science and Technology · doi:10.1021/es501955g · Cited by 175 · cited 1× · see citing works
“Here we used nominal cell culture medium concentrations; however, there are numerous parameters affecting actual exposure that need consideration (Armitage et al., 2014; Wambaugh et al., 2019).”
The PPARα-Dependent Rodent Liver Tumor Response Is Not Relevant to Humans: Addressing Misconceptions
Corton, J. C., Peters, J. M., & Klaunig, J. E. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2094-7 · Cited by 175 · cited 1× · see citing works
“Further, the BioMAP assays used human primary cells; even if these systems were responsive to PPAR agonists, the PPARa-linked liver toxicity for PFAS is argued as not relevant to human exposure (Corton et al., 2018).”
Grulke, C., Williams, A., Thillanadarajah, I., & Richard, A. (2019) · Computational Toxicology · doi:10.1016/j.comtox.2019.100096 · Cited by 161 · cited 1× · see citing works
“PFAS are arranged from lowest molecular weight to highest and represented by their respective DSSTox substance identifiers, or DTXSIDs (Grulke et al., 2019).”
Reboud-Ravaux, M. (2002) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-56373-7_7 · Cited by 151 · cited 2× · see citing works
“Proteasome inhibitors are used therapeutically as anticancer agents and drive cancer cells into apoptosis at appropriate concentrations (Kisselev and Goldberg, 2001).”
Bjork, J. A., & Wallace, K. B. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp093 · Cited by 137 · cited 14× · see citing works
“The European Food Safety Authority extensively reviewed both animal studies and human epidemiological associations of PFAS (primarily PFOA and PFOS) and reported decreased T cell-dependent antibody responses and reduced antibody response to vaccinations as critical indicators of PFAS effects (EFSA, 2020).”
InfluentialPatlewicz, G., Richard, A. M., Williams, A. J., Grulke, C. M., Sams, R., Lambert, J., Noyes, P. D., DeVito, M. J., Hines, R. N., Strynar, M., et al. (2019) · Environmental Health Perspectives · doi:10.1289/ehp4555 · Cited by 128 · cited 5× · see citing works
“…useful in developing a read-across approach for data gap-filling; whether the PFAS were technically feasible to test based on physicochemical considerations (solubility/volatility); and whether the PFAS helped to represent structural diversity among this group of chemicals (Patlewicz et al., 2019).”
InfluentialProfiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems
Houck, K., Dix, D., Judson, R., Kavlock, R., Yang, J., & Berg, E. (2009) · Journal of biomolecular screening · doi:10.1177/1087057109345525 · Cited by 101 · cited 1× · see citing works
“Cell type-selective cytotoxicity patterns were previously observed in testing other chemical classes (Houck et al., 2009).”
Self-citation13‐Week Dietary Toxicity Study of Ammonium Perfluorooctanoate (APFO) in Male Rats
Perkins, R. G., Butenhoff, J., Kennedy, G., & Palazzolo, M. (2004) · Drug and chemical toxicology (New York, N.Y. 1978) · doi:10.1081/dct-200039773 · Cited by 91 · cited 2× · see citing works
“…in the 12-assay BioMAP assay suite and absence of the liver toxicity signature for these PPAR agonists is of interest given that PPAR-like liver effects have been shown in vivo for a number of PFAS including PFOA and PFOS (Perkins et al., 2004; Bjork et al., 2008; Bjork and Wallace, 2009).”
Yang, D., Han, J., Hall, D. R., Sun, J., Fu, J., Kutarna, S., Houck, K. A., LaLone, C. A., Doering, J. A., Ng, C. A., et al. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.0c00049 · Cited by 90 · cited 1× · see citing works
“Indeed, PFAS have been shown to have significant effects on several properties including serum protein binding and bioaccumulation that may impact actual cellular exposure levels (Yang, D. et al., 2020; Zhang, W. et al., 2020).”
Self-citationThioredoxin Txnl1/TRP32 Is a Redox-active Cofactor of the 26 S Proteasome
Andersen, K. M., Madsen, L., Prag, S., Johnsen, A. H., Semple, C. A., Hendil, K. B., & Hartmann-Petersen, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900016200 · Cited by 88 · cited 1× · see citing works
“Here, too, crosstalk with the proteasome pathway has been shown through TXNL1, a thioreductase that plays a role in the transfer of misfolded nascent protein chain from the ribosome to the 26S proteasome, which was unprocessed upon MetAP2 inhibition (Andersen et al., 2009).”
The effect of azathioprine on gammaglobulin synthesis in man.
Levy, J., Barnett, E., Macdonald, N. S., Klinenberg, J., & Pearson, C. M. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107031 · Cited by 88 · cited 1×
“Reduced IgG is a reported effect in vivo for methotrexate and azathioprine when used for treatment of rheumatoid arthritis (Rackham et al., 2002; Kapetanovic et al., 2017; Levy et al., 1972).”
Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate.
Loveless, S., Hoban, D., Sykes, G. P., Frame, S., & Everds, N. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn113 · Cited by 87 · cited 1× · see citing works
“For example, systemic toxicity and stress in the whole animal has been postulated as a mechanism of multiple immune suppression effects for PFOS and PFOA, and these are modes-of-action that may not be captured in the BioMAP panel (Loveless et al., 2008).”
Perfluorooctane sulfonate-induced changes in fetal rat liver gene expression.
Bjork, J., Lau, C., Chang, S., Butenhoff, J., & Wallace, K. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.007 · Cited by 85 · cited 14× · see citing works
“The European Food Safety Authority extensively reviewed both animal studies and human epidemiological associations of PFAS (primarily PFOA and PFOS) and reported decreased T cell-dependent antibody responses and reduced antibody response to vaccinations as critical indicators of PFAS effects (EFSA, 2020).”
InfluentialSolvent Suitability for HFPO-DA (“GenX” Parent Acid) in Toxicological Studies
Liberatore, H. K., Jackson, S. R., Strynar, M. J., & McCord, J. P. (2020) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.0c00323 · Cited by 84 · cited 3× · see citing works
“One chemical, ammonium perfluoro-2-methyl-3-oxahexanoate (GenX), was solubilized in H 2 O as it was known to be unstable in DMSO (Gaballah et al., 2020; Liberatore et al., 2020).”
Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization.
Wambaugh, J., Wetmore, B., Ring, C. L., Nicolas, C. I., Pearce, R. G., Honda, G., Dinallo, R., Angus, D., Gilbert, J., Sierra, T., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz205 · Cited by 82 · cited 1× · see citing works
“Here we used nominal cell culture medium concentrations; however, there are numerous parameters affecting actual exposure that need consideration (Armitage et al., 2014; Wambaugh et al., 2019).”
Williams, A. J., Gaines, L. G. T., Grulke, C., Lowe, C. N., Sinclair, G., Samano, V. A., Thillainadarajah, I., Meyer, B., Patlewicz, G. Y., & Richard, A. M. (2022) · Frontiers in Environmental Science · doi:10.3389/fenvs.2022.850019 · Cited by 81 · cited 1× · see citing works
“…of PFAS, the OECD now defines PFAS as substances with a minimum of one perfluorinated carbon, which results in a list of PFAS that may approach 40,000 substances, with more stringent definitions of PFAS structures resulting in shorter lists in the thousands (Williams et al., 2022; OECD, 2021).”
Zhang, C., McElroy, A. C., Liberatore, H. K., Alexander, N. L. M., & Knappe, D. R. U. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.1c03979 · Cited by 78 · cited 1× · see citing works
“Evolving knowledge of instability of certain PFAS in DMSO (Liberatore et al., 2020; Zhang, C. et al., 2021) led to a stock quality and stability evaluation across the PFAS stocks employed in this work.”
Kunkel, E., Plavec, I., Nguyen, D., Melrose, J. E., Rosler, E., Kao, L., Wang, Y.-E., Hytopoulos, E., Bishop, A. C., Bateman, R., et al. (2004) · Assay and drug development technologies · doi:10.1089/adt.2004.2.431 · Cited by 77 · cited 2× · see citing works
“Preparation and co-culture of human primary cell types and methods for the systems were as previously described (Melton et al., 2013; Shah et al., 2017; Kunkel et al., 2004a).”
An integrative biology approach for analysis of drug action in models of human vascular inflammation
Kunkel, E., Dea, M., Ebens, A., Hytopoulos, E., Melrose, J. E., Nguyen, D., Ota, K. S., Plavec, I., Wang, Y.-E., Watson, S. R., et al. (2004) · The FASEB Journal · doi:10.1096/fj.04-1538fje · Cited by 76 · cited 2× · see citing works
“Preparation and co-culture of human primary cell types and methods for the systems were as previously described (Melton et al., 2013; Shah et al., 2017; Kunkel et al., 2004a).”
Popa-Burke, I. G., Issakova, O., Arroway, J. D., Bernasconi, P., Chen, M., Coudurier, L., Galasinski, S., Jadhav, A., Janzen, W., Lagasca, D., et al. (2004) · Analytical Chemistry · doi:10.1021/ac0491859 · Cited by 73 · cited 1×
“DMSO stock solutions were used as this is a universal solvent having good general small-molecule solvating capability and compatibility with high-throughput biological assays (Popa-Burke et al., 2004).”
Characterization of compound mechanisms and secondary activities by BioMAP analysis.
Berg, E., Kunkel, E., Hytopoulos, E., & Plavec, I. (2006) · Journal of pharmacological and toxicological methods · doi:10.1016/j.vascn.2005.06.003 · Cited by 66 · cited 3× · see citing works
“…as (patho)physiologically relevant screening assays for evaluating adverse effects was previously demonstrated through testing pharmaceuticals and clinical candidates as well as environmental chemicals in the EPA’s ToxCast program (Kleinstreuer et al., 2014; Berg et al., 2006; Singer et al., 2019).”
Facciotti, F., Larghi, P., Bosotti, R., Vasco, C., Gagliani, N., Cordiglieri, C., Mazzara, S., Ranzani, V., Rottoli, E., Curti, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917834117 · Cited by 63 · cited 1× · see citing works
“IL-10 IL-10 is a cytokine that promotes B cell IgG production (Facciotti et al., 2020; Itoh et al., 1994).”
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation
Betts, B., Bastian, D., Iamsawat, S., Nguyen, H. D., Heinrichs, J., Wu, Y., Daenthanasanmak, A., Veerapathran, A., O'Mahony, A., Walton, K., et al. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1712452115 · Cited by 62 · cited 1× · see citing works
“This panel has been extensively used in pharmaceutical and consumer products research for characterization of product candidates (O’Mahony et al., 2018; Betts et al., 2018; Hammitzsch et al., 2015; Shah et al., 2017; Simms et al., 2021; Singer et al., 2019).”
Fink, E. E., Mannava, S., Bagati, A., Bianchi-Smiraglia, A., Nair, J., Moparthy, K. C., Lipchick, B. C., Drokov, M., Utley, A., Ross, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.190 · Cited by 56 · cited 1×
“…acrylate and 1H,1H-perfluorooctyl acrylate showed similarity to auranofin, an antibiotic that can inhibit thioredoxin reductase, an enzyme that maintains cellular redox potential and whose expression can be repressed by the proteasome inhibitors bortezomib and carfilzomib (Fink et al., 2016).”
DeWitt, J., Copeland, C. B., & Luebke, R. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp040 · Cited by 55 · see citing works
Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man.
Bertino, J. (1973) · Arthritis & Rheumatism · doi:10.1002/art.1780160113 · Cited by 52 · cited 1×
“The exception was for azathioprine and methotrexate, which clustered similarly, both with mechanisms of action as antimetabolites inhibiting cell cycle S phase (Bertino, 1973).”
Singer, J., Al-fayoumi, S., Taylor, J., Velichko, S., & O'Mahony, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222944 · Cited by 51 · cited 2× · see citing works
“…as (patho)physiologically relevant screening assays for evaluating adverse effects was previously demonstrated through testing pharmaceuticals and clinical candidates as well as environmental chemicals in the EPA’s ToxCast program (Kleinstreuer et al., 2014; Berg et al., 2006; Singer et al., 2019).”
Kapetanovic, M., Nagel, J., Nordström, I., Saxne, T., Geborek, P., & Rudin, A. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.12.068 · Cited by 50 · see citing works
Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets
Berg, E. L., Yang, J. B., & Polokoff, M. A. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113505324 · Cited by 47 · cited 3× · see citing works
“This similarity search analysis relies on inference to data generated using BioMAP for a diverse set of chemicals (Berg, 2019; Berg et al., 2006, 2013).”
InfluentialMelton, A., Melrose, J. E., Alajoki, L., Privat, S., Cho, H., Brown, N., Plavec, A. M., Nguyen, D., Johnston, E. D., Yang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058966 · Cited by 44 · cited 2× · see citing works
“The levels of cell surface (or secreted, indicated by the prefix “s”) biomarker endpoints were measured by ELISA as described (Shah et al., 2017; Melton et al., 2013).”
Kumon, Y., Suehiro, T., Hashimoto, K., & Sipe, J. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00829.x · Cited by 42 · cited 1×
“5C), consistent with known activity of the glucocorticoids acting through the glucocorticoid receptor in aortic smooth muscle cells (Kumon et al., 2001).”
Itoh, K., Inoue, T., Ito, K., & Hirohata, S. (1994) · Cellular Immunology · doi:10.1006/cimm.1994.1243 · Cited by 39 · cited 2×
“IL-10 IL-10 is a cytokine that promotes B cell IgG production (Facciotti et al., 2020; Itoh et al., 1994).”
Lee, C. R., Chun, J., Kim, S.-Y., Park, S., Kim, S.-H., Park, E.-J., Kim, I.-S., Cho, N.-H., Kim, I.-G., So, I., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.05.009 · Cited by 36 · cited 1× · see citing works
“Such activity may be consistent with reported anticancer effects of cyclosporin A at micromolar concentrations, with activity attributed to inhibition of mTORC1 signaling in prostate cancer cells (Lee et al., 2012).”
Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases
Khalesi, N., Korani, S., Korani, M., Johnston, T., & Sahebkar, A. (2021) · InflammoPharmacology · doi:10.1007/s10787-021-00863-2 · Cited by 33 · cited 1× · see citing works
“Proteasome inhibitors have been previously reported to be immunosuppressive (Khalesi et al., 2021).”
New proteasome inhibitors in the treatment of multiple myeloma
Hungria, V. T. D. M., Crusoé, E. D. Q., Bittencourt, R., Maiolino, Â., Magalhães, R., Sobrinho, J., Pinto, J. V., Fortes, R., Moreira, E. D. S., & Tanaka, P. (2018) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.07.003 · Cited by 33 · cited 1× · see citing works
“Side effects of proteasome inhibitors reported in clinical trials include anemia, gastrointestinal disorders, and peripheral neuropathy (Hungria et al., 2019).”
Shah, F., Stepan, A., O'Mahony, A., Velichko, S., Folias, A. E., Houle, C., Shaffer, C. L., Marcek, J., Whritenour, J., Stanton, R., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.003 · Cited by 29 · cited 3× · see citing works
“The levels of cell surface (or secreted, indicated by the prefix “s”) biomarker endpoints were measured by ELISA as described (Shah et al., 2017; Melton et al., 2013).”
Berg, E., Polokoff, M., O'Mahony, A., Nguyen, D., & Li, X.-T. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16011008 · Cited by 19 · cited 1× · see citing works
“Target mechanisms associated with the thrombosis signature include mTOR, AhR, V-ATPase, lysosomal function, CYP17A, PKC NOD2, estrogen receptor, H1R, HIF-1alpha, thyroid hormone receptor, OSM R (Berg et al., 2015).”
Scepanovic, P., Alanio, C., Hammer, C., Hodel, F., Bergstedt, J., Patin, E., Thorball, C., Chaturvedi, N., Charbit, B., Abel, L., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0568-8 · Cited by 17 · cited 4× · see citing works
“This panel has been extensively used in pharmaceutical and consumer products research for characterization of product candidates (O'Mahony et al., 2018; Betts et al., 2018; Hammitzsch et al., 2015; Shah et al., 2017; Simms et al., 2021; Singer et al., 2019).”
InfluentialToxicity of perfluorinated fatty acids for human and murine B cell lines.
Levitt, D., & Liss, A. (1986) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(86)90394-7 · Cited by 17 · cited 1×
“The NTP monograph did not include supporting in vitro/mechanistic data for IgG suppression but did report no suppression of IgM in either murine or human B cell lines, even at very high (750 mM) concentrations of PFOA (Levitt and Liss, 1986).”
Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition
Berg, E. L. (2019) · Frontiers in Big Data · doi:10.3389/fdata.2019.00047 · Cited by 14 · cited 9× · see citing works
“The profiles for PFAS chemicals were also analyzed for the presence of defined toxicity signatures from previous work with the BioMAP assay suite (Berg, 2019).”
InfluentialSimms, L., Mason, E., Berg, E., Yu, F., Rudd, K., Czekala, L., Sticken, E. T., Brinster, O., Wieczorek, R., Stevenson, M., et al. (2021) · Current Research in Toxicology · doi:10.1016/j.crtox.2021.08.003 · Cited by 13 · cited 1×
“This panel has been extensively used in pharmaceutical and consumer products research for characterization of product candidates (O’Mahony et al., 2018; Betts et al., 2018; Hammitzsch et al., 2015; Shah et al., 2017; Simms et al., 2021; Singer et al., 2019).”
PPARα agonists based on stilbene and its bioisosteres: biological evaluation and docking studies
Filippis, B. D., Agamennone, M., Ammazzalorso, A., Bruno, I., D’Angelo, A., Matteo, M. D., Fantacuzzi, M., Giampietro, L., Giancristofaro, A., Maccallini, C., et al. (2015) · MedChemComm · doi:10.1039/c5md00151j · Cited by 12 · cited 1× · see citing works
“Profiles for PPARa agonists oleylethanolamide and gemfibrozil and PPARg agonists rosiglitazone and pioglitazone at concentrations exceeding their effective in vitro reported ones are shown in Figure 8 (Fu et al., 2003; De Filippis et al., 2015; Young et al., 1998; Sakamoto et al., 2000).”
Immunoglobulin levels in methotrexate treated paediatric rheumatology patients
Rackham, O., Sills, J., & Davidson, J. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.2.147 · Cited by 7 · cited 1×
“Reduced IgG is a reported effect in vivo for methotrexate and azathioprine when used for treatment of rheumatoid arthritis (Rackham et al., 2002; Kapetanovic et al., 2017; Levy et al., 1972).”
O'Mahony, A., John, M., Cho, H., Hashizume, M., & Choy, E. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1532-5 · Cited by 6 · cited 2× · see citing works
“This panel has been extensively used in pharmaceutical and consumer products research for characterization of product candidates (O’Mahony et al., 2018; Betts et al., 2018; Hammitzsch et al., 2015; Shah et al., 2017; Simms et al., 2021; Singer et al., 2019).”
Flagged first, then by citations
15 of the 90 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- CDC (2019). Fourth National Report on Human Exposure to Environmental Chemicals. Updated Tables, Volume One. doi: 10.15620/cdc75822 · DOI
- Gerçel-Taylor C, Ackermann MA and Taylor DD (2001). Evaluation of cell proliferation and cell death based assays in chemosensitivity testing. Anticancer Res 21, 2761– 2768. 11724352
- Young PW, Buckle DR, Cantello BC (1998). Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284, 751– 759. 9454824
Cited by
Sorted by citations
The EU’s Per- and Polyfluoroalkyl Substances (PFAS) Ban: A Case of Policy over Science
Spyrakis, F., & Dragani, T. A. (2023) · Toxics · doi:10.3390/toxics11090721 · Cited by 78 · see citing works
“The activity profile of PFOA shares some common features with that of dexamethasone, but also shows unique characteristics [41].”
BackgroundCarstens, K. E., Freudenrich, T. M., Wallace, K., Choo, S., Carpenter, A., Smeltz, M. G., Clifton, M. S., Henderson, W. M., Richard, A. M., Patlewicz, G. Y., et al. (2023) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00344 · Cited by 82 · see citing works
Qin, W.-P., Henneberger, L., Glüge, J., König, M., & Escher, B. (2024) · Environmental Science and Technology · doi:10.1021/acs.est.3c09950 · Cited by 28 · see citing works
Patlewicz, G., Judson, R., Williams, A., Butler, T., Barone, S., Carstens, K., Cowden, J., Dawson, J., Degitz, S., Fay, K., et al. (2024) · Computational Toxicology · doi:10.1016/j.comtox.2024.100327 · Cited by 25 · see citing works
Incorporating New Approach Methods (NAMs) Data in Dose-Response Assessments: The Future Is Now!
Lu, E.-H., Rusyn, I., & Chiu, W.-H. A. (2024) · Journal of Toxicology and Environmental Health. Part B, Critical Reviews · doi:10.1080/10937404.2024.2412571 · Cited by 20 · see citing works
Kreutz, A., Clifton, M. S., Henderson, W. M., Smeltz, M. G., Phillips, M., Wambaugh, J., & Wetmore, B. (2023) · Toxics · doi:10.3390/toxics11050463 · Cited by 20 · see citing works
Ford, L. C., Lin, H.-C., Zhou, Y.-H., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R. R., Chiu, W.-H. A., & Rusyn, I. (2024) · Human Genomics · doi:10.1186/s40246-024-00665-x · Cited by 17 · see citing works
“This finding corroborated our previous analysis in a single cardiomyocyte donor [22], as well as studies in other cell types [18, 19, 85].”
BackgroundResultFord, L. C., Lin, H., Tsai, H.-H. D., Zhou, Y., Wright, F. A., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Toxicology · doi:10.1016/j.tox.2024.153763 · Cited by 30 · see citing works
Wood, A., Atienzar, F., Basili, D., Coulet, M., Fernandez, R., Galano, M., Marin-Kuan, M., Montoya, G., Piechota, P., Punt, A., et al. (2025) · Regulatory toxicology and pharmacology : RTP · doi:10.1016/j.yrtph.2025.105863 · Cited by 14 · see citing works
Judson, R., Smith, D., Devito, M. J., Wambaugh, J., Wetmore, B., Friedman, K. P., Patlewicz, G., Thomas, R. S., Sayre, R. R., Olker, J. H., et al. (2024) · Toxics · doi:10.3390/toxics12040271 · Cited by 13 · see citing works
Patlewicz, G. Y., Judson, R., Friedman, K. P., Wetmore, B. A., DeVito, M. J., Harrill, J., Carstens, K. E., Houck, K. A., Wambaugh, J. F., Padilla, S., et al. (2025) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2025.2521615 · Cited by 12 · see citing works
Self-citationCrizer, D., Rice, J. R., Smeltz, M. G., Lavrich, K. S., Ravindra, K., Wambaugh, J., Devito, M. J., & Wetmore, B. (2024) · Toxics · doi:10.3390/toxics12090672 · Cited by 12 · see citing works
“…NAMs focus on multiple endpoints that cover a broad range of bioactivity including assays examining specific transcription factor activities [4]; panels that identify potential immunotoxicants [5]; developmental neurotoxicants [6]; thyroid targets [7]; and other bioactivity evaluations in progress.”
BackgroundTsai, H.-H. D., Ford, L. C., Chen, Z., Dickey, A. N., Wright, F. A., & Rusyn, I. (2024) · ALTEX · doi:10.14573/altex.2311031 · Cited by 9 · see citing works
“In addition, a study of 147 PFAS identified a trend between molecular weight and bioactivity related to in vitro immunosuppression (Houck et al., 2023), and a study of 160 PFAS discovered that compounds with long carbon chains (8 or more carbons), high carbon to fluorine ratio, or containing a…”
BackgroundClewell, H. J. (2024) · Regulatory toxicology and pharmacology : RTP · doi:10.1016/j.yrtph.2024.105738 · Cited by 5 · see citing works
Xuan, Y., Wang, Y.-L., Li, R., Zhong, Y.-Y., Wang, N., Zhang, L., Chen, Q., Yu, S., & Yuan, J.-T. (2024) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2024.2387733 · Cited by 3
“the immunotoxicity data on 146 PFass in human primary cells were collected from the literature (houck et al. 2023). this study defines immunosuppressive features as follows: t cell proliferation reduction feature with a significant response size of 20% (sag: Proliferation, log10Ratio < −0.1), or…”
InfluentialWang, H., Liang, Y., Sun, J.-R., Linares, J., Russell, W. K., & Khan, M. F. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.127367 · Cited by 1 · see citing works
Loan, A., Bradford, L. M., Nunnikhoven, A., Zhang, G., Dupuis, E., Cho, E., Meier, M., Aranda-Rodriguez, R., Tayabali, A., Eccles, K. M., et al. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04525-6
Ford, L. C., Lin, H.-C., Chiu, W.-H. A., & Rusyn, I. (2026) · Environmental Science and Technology · doi:10.1021/acs.est.5c18772
Range of the perfluorooctanoate (PFOA) safe dose for human health: an international collaboration
Clewell, H. J. (2025) · Journal of Toxicology and Regulatory Policy · doi:10.69982/jtrp-24-0005
- Authors
- Houck, K.
- Affiliations
- Environmental Protection Agency (US)
- Corresponding author
- Houck, Keith
- ORCID
- Houck, Keith
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2022
- Volume
- 40
- Issue
- 2
- Pages
- 248–270-248–270
- ISSN
- 0946-7785 (ISSN-L)
- 1868-596X
- PMC
- PMC10331698
- OpenAlex
- W4296713605
- Cited by
- 20
- References
- 90
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- ALTEX (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- Funders
- U.S. Environmental Protection Agency
- Topics
- Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Fluorine in Organic Chemistry
- Keywords
- per- and polyfluoroalkyl substances, PFAS, immunotoxicity, immunosuppression, primary human cells, phenotypic screening, PFOS, perfluorooctanoic acid, dexamethasone, ubiquitin ligase inhibitors, thioredoxin reductase inhibitors, mechanism of action, safety assessment, biomarkers
- MeSH terms
- Caprylates, Environmental Pollutants, Fluorocarbons, Humans, Alkanesulfonic Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review